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Abstract
Background: Although serotonin (5-HT3) receptor antagonists are effective in reducing nausea and vomiting,
they may be associated with increased cardiac risk. Our objective was to examine the comparative safety and
effectiveness of 5-HT3 receptor antagonists (e.g., dolasetron, granisetron, ondansetron, palonosetron, tropisetron)
alone or combined with steroids for patients undergoing chemotherapy.
Methods: We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception
until December 2015 for studies comparing 5-HT3 receptor antagonists with each other or placebo in chemotherapy
patients. The search results were screened, data were abstracted, and risk of bias was appraised by pairs of reviewers,
independently. Random-effects meta-analyses and network meta-analyses (NMAs) were conducted.
Results: After screening 9226 citations and 970 full-text articles, we included 299 studies (n = 58,412 patients).
None of the included studies reported harms for active treatment versus placebo. For NMAs on the risk of
arrhythmia (primary outcome; three randomized controlled trials [RCTs], 627 adults) and mortality (secondary
outcome; eight RCTs, 4823 adults), no statistically significant differences were observed between agents.
A NMA on the risk of QTc prolongation showed a significantly greater risk for dolasetron + dexamethasone
versus ondansetron + dexamethasone (four RCTs, 3358 children and adults, odds ratio 2.94, 95% confidence
interval 2.13–4.17).
For NMAs on the number of patients without nausea (44 RCTs, 11,664 adults, 12 treatments), number
of patients without vomiting (63 RCTs, 15,460 adults, 12 treatments), and number of patients without
chemotherapy-induced nausea or vomiting (27 RCTs, 10,924 adults, nine treatments), all agents were
significantly superior to placebo. For a NMA on severe vomiting (10 RCTs, 917 adults), all treatments
decreased the risk, but only ondansetron and ramosetron were significantly superior to placebo. According
to a rank-heat plot with the surface under the cumulative ranking curve results, palonosetron + steroid was
ranked the safest and most effective agent overall.
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Conclusions: Most 5-HT3 receptor antagonists were relatively safe when compared with each other, yet none of the
studies compared active treatment with placebo for harms. However, dolasetron + dexamethasone may prolong the
QTc compared to ondansetron + dexamethasone. All agents were effective for reducing risk of nausea, vomiting, and
chemotherapy-induced nausea or vomiting.
Trial registration: This study was registered at PROSPERO: (CRD42013003564).
Keywords: Chemotherapy, Systematic review, Network meta-analysis, Serotonin receptor antagonists, Effectiveness, Safety
Background
Cancer is the leading cause of death worldwide, accounting
for 8.2 million deaths in 2012. Chemotherapy is a major
component of cancer therapy. However chemotherapy-in-
duced nausea and vomiting (CINV) are common, af-
fecting approximately 70–80% of patients who receive
chemotherapy, and can be debilitating [1]. CINV
cause significant anxiety [2, 3]; decrease quality of life
[4, 5]; and can result in dehydration, electrolyte im-
balance [6, 7], and hospital admission [8].
Serotonin (5-HT3) receptor antagonists are antiemetic
medications that act by inhibiting the vagal nerves in the
central nervous system and intestinal mucosa that trigger
the emetic reflex [6, 9–11]. Examples of first-generation 5-
HT3 receptor antagonists include dolasetron, granisetron,
and ondansetron, while palonosetron is a second-
generation receptor antagonist [12]. These treatments can
be administered orally, subcutaneously, or intravenously.
Previous systematic reviews have found that 5-HT3 recep-
tor antagonists are effective for treating nausea and vomit-
ing that occur after chemotherapy [13–16]. As such, 5-HT3
receptor antagonists are recommended as the first-line of
treatment for CINV in both adults and children [9].
Although 5-HT3 receptor antagonists are effective in
reducing nausea and vomiting, concerns have been
raised that they may be associated with increased risk of
arrhythmia. Some evidence suggests that they prolong
the QT interval on electrocardiography [17, 18], which
is associated with an increased risk of serious ventricular
arrhythmias (e.g., torsades de pointes). In vitro studies
have indicated that 5-HT3 receptor antagonists block
voltage-dependent sodium channels and human ether-a-
go-go-related gene potassium channels (cardiac ion
channels), with the magnitude and type of electrocardio-
graphic change depending on the particular drug. The
US Food and Drug Administration [19] and Health
Canada (a division of the Canadian federal government)
[20] have published warnings on the safety of dolasetron
but no warnings have appeared for other 5-HT3 receptor
antagonists. Information about cardiac risks cannot be
gleaned from previous systematic reviews of 5-HT3 recep-
tor antagonists [13–16] because cardiac safety was not ex-
amined in those studies. This systematic review was
undertaken, at the request of Canadian policy-makers
from Health Canada, to determine the comparative safety




A systematic review protocol was drafted, revised, regis-
tered in the PROSPERO database (CRD42013003564),
and published in a peer-reviewed, open-access journal
[21]. Because the full methods have already been reported
(Additional file 1), they are described only briefly below.
We used the PRISMA extension to network meta-analysis
(NMA) to report our results (Additional file 2) [22] and
our analysis was conducted according to the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) guidance [23].
Data sources and searches
The primary information sources were MEDLINE,
Embase, and the Cochrane Central Register of Con-
trolled Trials, which were searched from inception until
11 December 2015. The full literature search for MED-
LINE has been published previously [21]. To supplement
the primary sources, we scanned the reference lists of
included studies and relevant reviews [24–27], and
searched conference abstracts and trial registries.
Study selection, data extraction, and quality assessment
Studies involving patients of any age undergoing chemo-
therapy and receiving a 5-HT3 receptor antagonist (i.e.,
dolasetron, granisetron, ondansetron, palonosetron, ramo-
setron, tropisetron) alone or combined with steroids
(dexamethasone, methylprednisolone, prednisone)
were included, regardless of publication status, dur-
ation of administration of the intervention, or dur-
ation of follow-up. Studies published in languages
other than English were excluded.
After a calibration exercise, pairs of reviewers independ-
ently screened the titles and abstracts of citations and the
full-text articles of potentially relevant studies, and then
abstracted data from included studies. Disagreements were
resolved through consensus or the involvement of an arbi-
trator (ACT). The following types of data were abstracted
from the included studies a priori: study characteristics,
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patient characteristics, and outcomes. The primary
outcome of interest, as identified by policy-makers
with Health Canada, was the number of patients ex-
periencing arrhythmia. Secondary outcomes included
the numbers of patients experiencing QTc prolonga-
tion, QRS interval prolongation, death, sudden cardiac
death, delirium, no nausea, no vomiting, no CINV,
and severe vomiting.
Randomized controlled trials (RCTs), non-RCTs, and
controlled before–after studies were assessed for quality
and risk of bias using the Cochrane Effective Practice
and Organisation of Care risk-of-bias tool [28]. Cohort
studies were assessed using the Newcastle–Ottawa Scale
[29]. The quality of reporting of harm outcomes was ap-
praised using the McMaster Quality Assessment Scale of
Harm (McHarm) tool [30]. Potential conflicts of interest
were recorded for all studies. Pairs of reviewers inde-
pendently appraised methodological quality and conflicts
were resolved through discussion.
Data synthesis and analysis
Random-effects meta-analysis and NMA were conducted.
Meta-analysis utilizes summary point estimates derived
from all participants enrolled in a trial, allowing for reli-
able investigation of treatment effects. NMA allows for
the comparison of multiple treatments in a comprehensive
analysis and the determination of the best treatment
among several competing treatments, including those that
have never been compared in a head-to-head study [31].
For outcomes for which two or more studies compar-
ing two interventions were available, we conducted a
meta-analysis for each outcome. We assessed dichotom-
ous outcomes and estimated the treatment effect for
each pairwise comparison using the odds ratio (OR) and
a 95% confidence interval (CI). We excluded studies that
reported zero events across all treatment arms. We an-
ticipated that treatment effects would vary according to
patient and study characteristics, and therefore used a
random-effects model, estimating the between-study
variance with the restricted maximum likelihood
method [32]. Statistical heterogeneity was quantified
with the I2 statistic [33], whereas clinical and meth-
odological heterogeneity was assessed subjectively by
the study team.
Before embarking on the NMA for each outcome, we
drew a network diagram to ensure that the included
studies formed a connected network. Potential effect
modifiers, specifically, age (adults and elderly versus
children) and type of chemotherapy (cisplatin versus
other), were identified before NMA was performed and
separate network diagrams were drawn with edges
colored according to the potential effect modifiers, to
ensure balance across treatment comparisons [34].
Random-effects NMA was then conducted using the
network command in Stata 13.0 [35, 36]. Predictive
intervals were calculated to observe the range within
which the effect estimate would lie should another
study be available [37].
The primary analysis was limited to RCTs, with non-
randomized studies included in an additional analysis to
evaluate the robustness of the results. Subgroup analysis
was conducted to determine whether the results chan-
ged according to the potential effect modifiers. We used
the design-by-treatment interaction model [38, 39] to
evaluate consistency over the entire network, accounting
for potential disagreement both between designs (e.g.,
two-arm versus three-arm trials) and between direct and
indirect evidence. When we identified statistically signifi-
cant global inconsistency, we examined local inconsist-
ency in each closed loop of the network using the loop-
specific method [40, 41]. We checked inconsistent loops
for potential data abstraction errors, as suggested by the
loop-specific method; if such errors were identified, we
repeated the analyses. Statistically significant inconsist-
ency and important heterogeneity were explored with
subgroup and sensitivity analyses. Similar to the pairwise
meta-analysis, all NMAs were performed within a fre-
quentist framework with a random-effects model assum-
ing a common within-network heterogeneity variance
across all comparisons, estimated with the restricted
maximum likelihood method [40, 41]. Ondansetron was
considered usual care in NMAs for which a placebo was
missing. Given that it is clinically reasonable to expect the
same between-study heterogeneity variance for the same
class of interventions, we assumed that all treatment com-
parisons within the network were associated with the
same magnitude of heterogeneity. The surface under the
cumulative ranking (SUCRA) curve was used to rank the
safety and effectiveness of the various 5-HT3 receptor an-
tagonists [42] and displayed using the rank-heat plot [43].
We conducted sensitivity analyses to ensure that poor-
quality studies did not bias the results. Specifically, we
conducted separate analyses for RCTs with low risk of
bias on the randomization component, the allocation
concealment component, or the blinding component, as
well as analyses in which the RCTs were combined with
other study designs. Selective outcome reporting and
reporting bias (e.g., small-study effects) were assessed
using the comparison-adjusted funnel plot for outcomes
with at least 10 studies in the network, coding treat-
ments from oldest to newest [34].
Results
Literature search
After screening 9226 citations and 970 full-text articles,
we included 299 studies (Additional file 3: Appendix A)
that enrolled a total of 58,412 patients (Fig. 1). Six of
these studies were conference abstracts that reported
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relevant unpublished data [Adel et al. 2006, Tabei et
al. 2006, Trifilio et al. 2006, Carreca et al. 2007,
Kadota et al. 2007, Piyush 2011]. The 299 studies
were reported in 295 primary publications. An add-
itional 18 companion reports were used for supple-
mentary material only.
Study and patient characteristics
The included studies were published between 1985 and
2015, with the largest proportion (based on 5-year inter-
vals) appearing between 1995 and 1999, and nearly half
were conducted in Europe (Table 1, Additional file 3:
Appendix B). More than 80% of the studies used an
RCT design, and more than 40% involved multiple
centers. The most commonly examined 5-HT3 recep-
tor antagonist was ondansetron. More than 60% of
the studies were limited to adults (age ≥ 18 years)
(Table 2, Additional file 3: Appendix C). Lung cancer
was the most common diagnosis, and more than half
of the chemotherapy regimens included cisplatin.
Concomitant radiotherapy was reported in less than
5% of the studies.
Methodological quality and risk of bias results
Two hundred and forty-six of the studies were assessed
with the Cochrane Effective Practice and Organisation of
Care risk-of-bias tool (Additional file 3: Appendices D, E).
Overall, more than half of the studies were assessed as
unclear on all of the following components: random se-
quence generation, allocation concealment, baseline out-
come measure similarities between treatment groups,
blinding, contamination, selective outcome reporting, and
other bias.
The 19 cohort studies were assessed using the New-
castle–Ottawa Scale. More than half of the studies
did not ensure the outcome of interest (e.g., incidence
of nausea) was present at the beginning of the study,
control for potential confounders, or report the
follow-up duration (Additional file 3: Appendix F).
With regard to sources of funding, 153 of the 299
studies did not report the source of funding, 127 were
funded by pharmaceutical companies, 17 were publicly
funded, and two reported no funding was received.
Reporting bias and small-study effects were not observed
across the comparison-adjusted funnel plots for all out-
comes (Additional file 3: Appendix G).
Fig. 1 Study flow chart
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Table 1 Summary of study characteristics














North America 79 26.42
Asia 65 21.74
Multi-continent 19 6.35
South America 4 1.34
Africa 2 0.67
Australia 0 0.00




















>1 Week 33 11.0
Not reported 12 4.0
Interventions examined: frequencyc
Serotonin antagonists: reported as administered alone (administered
with corticosteroid)
Ondansetron 115 (69) 38.46 (23.08)
Granisetron 88 (55) 29.43 (18.39)
Tropisetron 23 (9) 7.69 (3.01)
Table 1 Summary of study characteristics (Continued)
Dolasetron 19 (7) 6.35 (2.34)
Ramosetron 11 (6) 3.68 (2.01)
Palonosetron 14 (22) 4.68 (7.36)
Comparator antiemetics:
Metoclopramide 21 7.0
Metoclopramide + steroid 18 6.0
Steroid 3 1.0
Chlorpromazine + steroid 2 0.7
Prochlorperazine 2 0.7
Azasetron + steroid 1 0.3
Chlorpromazine 1 0.3
Metopimazine + steroid 1 0.3
Prochlorperazine + steroid 1 0.3
Serotonin antagonists given with other antiemetic:
Ondansetron + steroid +metoclopramide 6 2.1
Granisetron + steroid +metoclopramide 6 2.0
Ondansetron +metoclopramide 2 0.7
Granisetron +metoclopramide 1 0.4
Ondansetron +metopimazine 1 0.4
Tropisetron +metopimazine 1 0.4
Granisetron + steroid + prochlorperazine 1 0.4
Ondansetron + steroid + prochlorperazine 1 0.4
Palonosetron + steroid + prochlorperazine 1 0.4
Tropisetron + steroid + metoclopramide 1 0.4








Sudden cardiac death 3 1.0




Not specified/not reported 101 33.8
CBA controlled before–after, CINV chemotherapy-induced nausea and vomiting,
NRCT non-randomized controlled trial, RCT randomized controlled trial
aIncludes unpublished data from conference abstracts and trial protocols
(Adel et al. 2006, Tabei et al. 2006, Trifilio et al. 2006, Carreca et al. 2007,
Kadota et al. 2007, Piyush 2011)
b Duration is in days unless otherwise noted
c Multiple interventions and comparators examined across the studies
d Multiple interventions and outcomes reported per study
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Results of statistical analysis
Number of patients experiencing harms
NMA for the primary outcome of arrhythmia was
attempted using three RCTs (n = 627 adults) investigating
dolasetron, granisetron, palonosetron, and/or granisetron
+ dexamethasone (Fig. 2, Additional file 3: Appendix H).
A fourth RCT was excluded from the analysis because it
reported zero events in all treatment arms [44]. The NMA
showed no statistically significant effects (Table 3, Fig. 3,
Additional file 3: Appendix H). The safest treatment ac-
cording to the SUCRA was granisetron (83% probability,
Fig. 3). None of the three RCTs examined the same inter-
vention so pairwise meta-analysis was not feasible. The in-
dividual results of each trial were not statistically
significant, as follows: granisetron versus dolasetron
(n = 311 patients, OR = 0.21, 95% CI = 0.02–1.84), granise-
tron + dexamethasone versus granisetron (n = 266 pa-
tients, OR = 3.12, 95% CI = 0.12–80.39), and palonosetron
versus granisetron (n = 50 patients, OR = 1.59, 95% CI =
0.58–4.30).
NMA for the secondary outcome of mortality was con-
ducted with eight RCTs (n = 4823 adults) investigating
dolasetron, granisetron, ondansetron (usual care), palono-
setron, tropisetron, granisetron + dexamethasone, metoclo-
pramide + dexamethasone, ondansetron + dexamethasone,
and/or palonosetron + dexamethasone (Fig. 2). A ninth
study was excluded from the analysis because it reported
zero events in all treatment arms [45], and another study
was excluded because it was not connected to the network
[46]. The NMA showed no statistically significant effects
(Table 3, Additional file 3: Appendix H). The safest treat-
ment according to the SUCRA was palonosetron + dexa-
methasone (93% probability, Fig. 3). In addition, three
pairwise meta-analyses were possible for the following
treatment comparisons, which were not statistically signifi-
cant: palonosetron + dexamethasone versus granisetron +
dexamethasone (three RCTs, n = 2638 adults, OR = 0.33,
95% CI = 0.09–1.18), ondansetron + dexamethasone versus
ondansetron (two RCTs, n = 313 adults, OR = 0.53, 95% CI
= 0.11–2.58), and palonosetron + dexamethasone versus
ondansetron + dexamethasone (two RCTs, n = 1101 adults,
OR = 0.33, 95% CI = 0.04–2.78).
NMA for the secondary outcome QTc prolongation
included four RCTs investigating dolasetron + dexa-
methasone, granisetron, granisetron + dexamethasone,
ondansetron (usual care), ondansetron + dexametha-
sone, palonosetron, and palonosetron + dexamethasone
(n = 3358 children and adults, Fig. 2). A fourth RCT was
excluded from the analysis because it reported zero events
in all treatment arms [38]. The NMA showed that patients
taking ondansetron + dexamethasone administration had
statistically significantly lower odds of QTc prolongation
compared to patients taking dolasetron + dexamethasone
(OR = 0.34, 95% CI = 0.24–0.47) (Table 3, Additional file 3:
Table 2 Summary of patient characteristics
Patient characteristics Number of studies
(n = 299)a, b
Percentage
of studies
Number of patients 58,412
Mean (median sample size) 197 (105)c
Mean % female 53.1d
Age category
Adults and elderly (aged ≥18 years) 192 64.21
Adults only (aged ≥18 to ≤65 years) 56 18.73
Children only (aged <18 years) 25 8.36
All ages 10 3.34
Children and adults (aged
≤65 years)
8 2.68
Not reported 8 2.68
Cancer typee




Unspecified or unknown 87 29.10




Not reported 43 14.38
Nervous system 13 4.35
Skin 11 3.68
Optic 5 1.67





Cisplatin administeredf 177 59.20
Cisplatin dose≥ 50 mg/m2 116 38.80




History of motion sickness 19 6.35
History of CINV 29 9.70
CINV chemotherapy induced nausea and vomiting
aIncludes unpublished data from conference abstracts and trial protocols (Adel
et al. 2006, Tabei et al. 2006, Trifilio et al. 2006, Carrec et al. 2007, Kadota et al.
2007, Piyush 2011)
bExcept where indicated otherwise
cOne study did not report sample size (n = 1)
dEighteen studies did not report female population size (n = 18)
eThe majority of studies included patients with different diagnoses
fIncludes the 116 studies with a cisplatin dose ≥ 50 mg/m2
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Appendix H). The safest treatment according to the
SUCRA was palonosetron + dexamethasone (83% prob-
ability). None of the four RCTs examined the same inter-
vention so pairwise meta-analysis was not feasible.
Consistent with the NMA results, only one of the individ-
ual results of the four RCTs was statistically significant
(ondansetron + dexamethasone versus dolasetron + dexa-
methasone, n = 696 patients, OR= 0.34, 95% CI = 0.24–
0.47). The other results were as follows: ondansetron ver-
sus granisetron (n = 1056 patients, OR = 7.92, 95% CI =
0.44–143.67), palonosetron versus granisetron (n = 597
patients, OR = 2.80, 95% CI = 0.06–141.54), palonosetron
+ dexamethasone versus granisetron + dexamethasone (n
= 1119 patients, OR = 0.84, 95% CI = 0.42–1.68), palono-
setron versus ondansetron (n = 773 patients, OR =
0.35, 95% CI = 0.02–6.42), and palonosetron + dexa-
methasone versus ondansetron + dexamethasone (n =
330 children, OR = 0.20, 95% CI = 0.01–4.10).
NMA and pairwise meta-analysis were not feasible for
the secondary outcomes of sudden cardiac death, delirium,
and QRS interval prolongation because only one RCT was
available for each of these outcomes. For sudden cardiac
death, the results were not statistically significant between
ondansetron and ondansetron + dexamethasone (n = 213
patients, OR = 2.73, 95% CI = 0.11–67.80). For delirium,
there were no statistically significant results for any of the
treatment comparisons, including metoclopramide + dexa-
methasone versus granisetron (n = 361 patients, OR = 4.14,
95% CI = 0.86–19.93), metoclopramide + dexamethasone
versus granisetron + dexamethasone (n = 478 patients,
OR = 4.07, 95% CI = 0.85–19.59), or granisetron versus
granisetron + dexamethasone (n = 597 patients, OR =
0.98, 95% CI = 0.01–7.10). For QRS interval prolonga-
tion, the available RCT only reported results for more
than 24 h of chemotherapy; ondansetron administered
on days 1–7 plus dexamethasone resulted in statisti-
cally significantly fewer patients experiencing a pro-
longed QRD interval when compared to dolasetron +
dexamethasone (OR = 0.29, 95% CI = 0.19–0.48).
When the studies reporting these harms were appraised
using the McHarm tool (Additional file 3: Appendices I,
J), the majority were assessed as unclear or partially fulfill-
ing all 15 criteria other than active collection of mode of
harm, timing and frequency of harms collection, use of
Fig. 2 Network plots for all network meta-analyses of the primary analysis. Abbreviations: DOLA dolasetron, STER steroid, GRAN granisetron, DEX
dexamethasone, METO metoclopramide, ONDA ondansetron, PALO palonosetron, PLAC placebo, RAMO ramosetron, TROP tropisetron. *ONDA +
DEX and PALO + DEX included only children
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Table 3 Statistically significant results of network meta-analysis in randomized controlled trials




Arrhythmia – 3 RCTs, 4 (inconsistency not applicableb)
No statistically significant results
Mortality – 8 RCTs, 7 treatments, 4823 adults
No statistically significant results
Evaluation of inconsistency using the design-by-treatment
interaction model
Chi-squared test: 1.06 P-value: 0.79
Degrees of freedom: 3 Heterogeneity: 0.00
QTc prolongation – 4 RCTs, 7 treatments, 3358 children and adults (inconsistency not applicableb)
Ondansetron + dexamethasone vs dolasetron + dexamethasone 1 0.34 (0.24–0.47) 0.34 (0.24–0.47)
Number of patients without nausea – 44 RCTS, 12 treatments plus placebo, 11,664 adults
Ondansetron + steroid vs ondansetron 8 1.96 (1.59–2.41) 2.16 (1.45–3.23)
Ondansetron + steroid vs granisetron 1 2.00 (1.63–2.45) 21.00 (3.35–131.51)
Ondansetron + steroid vs dolasetron NA 2.09 (1.47–2.97) NA
Ondansetron + steroid vs dolasetron + steroid NA 0.44 (0.20–0.96) NA
Ondansetron + steroid vs palonosetron NA 1.60 (1.06–2.41) NA
Ondansetron + steroid vs tropisetron + steroid 1 2.40 (1.49–3.88) 7.20 (2.03–25.51)
Ondansetron + steroid vs placebo NA 337.68 (18.89–6035.72) NA
Granisetron + steroid vs ondansetron NA 1.91 (1.55–2.34) NA
Granisetron + steroid vs granisetron 6 1.95 (1.62–2.34) 1.96 (1.54–2.50)
Granisetron + steroid vs dolasetron NA 2.04 (1.44–2.87) NA
Granisetron + steroid vs dolasetron + steroid NA 0.43 (0.20–0.93) NA
Granisetron + steroid vs palonosetron NA 1.55 (1.04–2.33) NA
Granisetron + steroid vs tropisetron + steroid 1 2.34 (1.45–3.77) 7.20 (1.29–40.05)
Granisetron + steroid vs placebo NA 328.52 (18.40–5864.44) NA
Ondansetron vs dolasetron + steroid NA 0.22 (0.10–0.48) NA
Ondansetron vs palonosetron + steroid NA 0.53 (0.39–0.73) NA
Ondansetron vs tropisetron + steroid NA 0.29 (0.13–0.62) NA
Ondansetron vs ramosetron + steroid NA 0.35 (0.19–0.64) NA
Ondansetron vs placebo NA 172.34 (9.67–3070.30) NA
Granisetron vs dolasetron + steroid NA 0.22 (0.10–0.47) NA
Granisetron vs palonosetron + steroid NA 0.52 (0.39–0.70) NA
Granisetron vs tropisetron + steroid NA 0.28 (0.13–0.61) NA
Granisetron vs ramosetron + steroid NA 0.34 (0.19–0.62) NA
Granisetron vs placebo 1 168.85 (9.51–2996.71) 169.00 (9.52–2999.80)
Dolasetron vs dolasetron + steroid 1 0.21 (0.10–0.42) 0.21 (0.10–0.42)
Dolasetron vs palonosetron + steroid NA 0.50 (0.33–0.76) NA
Dolasetron vs tropisetron + steroid NA 0.27 (0.12–0.61) NA
Dolasetron vs ramosetron + steroid NA 0.33 (0.17–0.63) NA
Dolasetron vs placebo NA 161.31 (8.95–2907.94) NA
Dolasetron + steroid vs palonosetron NA 3.65 (1.68–7.94) NA
Dolasetron + steroid vs palonosetron + steroid NA 2.39 (1.06–5.39) NA
Dolasetron + steroid vs tropisetron + steroid NA 5.49 (2.27–13.27) NA
Dolasetron + steroid vs ramosetron + steroid NA 3.19 (1.29–7.85) NA
Dolasetron + steroid vs placebo NA 771.35 (39.35–15,120.97) NA
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Table 3 Statistically significant results of network meta-analysis in randomized controlled trials (Continued)
Palonosetron vs tropisetron + steroid NA 0.35 (0.15–0.83) NA
Palonosetron vs ramosetron + steroid NA 0.43 (0.22–0.86) NA
Palonosetron vs placebo NA 211.46 (11.64–3841.31) NA
Palonosetron + steroid vs tropisetron + steroid NA 2.30 (1.35–3.91) NA
Palonosetron + steroid vs placebo NA 323.08 (17.93–5821.31) NA
Tropisetron + steroid vs tropisetron + steroid 2 0.24 (0.13–0.44) 0.24 (0.13–0.44)
Tropisetron + steroid vs ramosetron + steroid NA 0.29 (0.14–0.60) NA
Tropisetron + steroid vs placebo NA 140.45 (7.63–2585.40) NA
Tropisetron + steroid vs placebo NA 597.18 (30.37–11,744.01) NA
Ramosetron + steroid vs ramosetron + steroid 1 0.49 (0.31–0.78) 0.48 (0.29–0.79)
Ramosetron + steroid vs placebo NA 242.02 (13.10–4471.01) NA
Ramosetron + steroid vs placebo NA 490.92 (26.08–9241.08) NA
Evaluation of inconsistency using the design-by-treatment
interaction model
Chi-squared test: 15.91 P-value: 0.1955
Degrees of freedom: 12 Heterogeneity: 0.00
Number of patients without vomiting – 63 RCTs, 12 treatments plus placebo, 15,460 adults
Ondansetron + steroid vs ondansetron 9 2.46 (1.80–3.37) 2.47 (1.52–4.03)
Ondansetron + steroid vs granisetron 1 2.35 (1.70–3.25) 21.00 (3.35–131.51)
Ondansetron + steroid vs dolasetron NA 2.83 (1.78–4.51) NA
Ondansetron + steroid vs tropisetron 1 2.95 (1.76–4.94) 7.20 (2.03–25.51)
Ondansetron + steroid vs placebo NA 31.56 (11.42–87.23) NA
Granisetron + steroid vs ondansetron NA 2.31 (1.66–3.21) NA
Granisetron + steroid vs granisetron 8 2.21 (1.64–2.96) 2.40 (1.21–4.75)
Granisetron + steroid vs dolasetron NA 2.66 (1.66–4.27) NA
Granisetron + steroid vs tropisetron 1 2.77 (1.65–4.66) 34.52 (1.83–650.54)
Granisetron + steroid vs placebo NA 29.64 (10.74–81.82) NA
Ondansetron vs dolasetron + steroid NA 0.46 (0.24–0.89) NA
Ondansetron vs palonosetron 2 0.59 (0.39–0.89) 0.44 (0.27–0.73)
Ondansetron vs palonosetron + steroid NA 0.33 (0.18–0.59) NA
Ondansetron vs tropisetron + steroid NA 0.32 (0.12–0.85) NA
Ondansetron vs ramosetron + steroid NA 0.37 (0.17–0.83) NA
Ondansetron vs placebo 3 12.82 (4.85–33.94) 11.02 (3.30–36.84)
Granisetron vs dolasetron + steroid NA 0.48 (0.25–0.94) NA
Granisetron vs palonosetron 3 0.62 (0.42–0.92) 0.69 (0.48–0.98)
Granisetron vs palonosetron + steroid NA 0.35 (0.20–0.62) NA
Granisetron vs tropisetron + steroid NA 0.34 (0.13–0.90) NA
Granisetron vs ramosetron + steroid NA 0.39 (0.18–0.87) NA
Granisetron vs placebo 1 13.44 (5.02–35.96) 78.00 (6.24–974.67)
Dolasetron vs dolasetron + steroid 1 0.40 (0.20–0.80) 0.21 (0.09–0.50)
Dolasetron vs palonosetron 1 0.51 (0.32–0.83) 0.55 (0.36–0.85)
Dolasetron vs palonosetron + steroid NA 0.29 (0.15–0.57) NA
Dolasetron vs tropisetron + steroid NA 0.28 (0.10–0.79) NA
Dolasetron vs ramosetron + steroid NA 0.32 (0.14–0.78) NA
Dolasetron vs placebo NA 11.14 (3.94–31.49) NA
Dolasetron + steroid vs tropisetron NA 2.61 (1.20–5.69) NA
Dolasetron + steroid vs placebo NA 27.92 (8.62–90.43) NA
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Table 3 Statistically significant results of network meta-analysis in randomized controlled trials (Continued)
Palonosetron vs tropisetron NA 2.02 (1.13–3.63) NA
Palonosetron vs placebo NA 21.65 (7.60–61.72) NA
Palonosetron + steroid vs tropisetron NA 3.62 (1.78–7.37) NA
Palonosetron + steroid vs ramosetron NA 2.24 (1.02–4.91) NA
Palonosetron + steroid vs placebo NA 38.78 (12.56–119.76) NA
Tropisetron vs tropisetron + steroid 2 0.27 (0.11–0.64) 0.27 (0.13–0.57)
Tropisetron vs ramosetron + steroid NA 0.31 (0.13–0.77) NA
Tropisetron vs placebo NA 10.70 (3.69–31.01) NA
Tropisetron + steroid vs placebo NA 39.86 (10.09–157.37) NA
Ramosetron vs placebo 1 17.30 (6.20–48.30) 10.45 (2.21–49.38)
Ramosetron + steroid vs placebo NA 34.31 (10.33–113.92) NA
Evaluation of inconsistency using the design-by-treatment
interaction model
Chi-squared test: 22.14 P-value: 0.1387
Degrees of freedom: 16 Heterogeneity: 0.10
Number of patients without CINV – 27 RCTs, 10
treatments, 10,924 adults
Ondansetron + steroid vs ondansetron 1 2.16 (1.62–2.87) 1.96 (1.12–3.42)
Ondansetron + steroid vs granisetron NA 2.17 (1.73–2.72) NA
Ondansetron + steroid vs palonosetron + steroid NA 0.81 (0.67–0.98) NA
Ondansetron + steroid vs tropisetron NA 4.18 (1.99–8.77) NA
Ondansetron + steroid vs placebo NA 365.96 (20.44–6553.02) NA
Granisetron + steroid vs ondansetron NA 2.23 (1.69–2.93) NA
Granisetron + steroid vs granisetron 6 2.24 (1.83–2.74) 2.35 (1.88–2.94)
Granisetron + steroid vs palonosetron + steroid NA 0.84 (0.70–0.99) NA
Granisetron + steroid vs tropisetron NA 4.31 (2.07–9.01) NA
Granisetron + steroid vs placebo NA 378.03 (21.15–6756.45) NA
Ondansetron vs palonosetron + steroid NA 0.38 (0.27–0.52) NA
Ondansetron vs ramosetron + steroid NA 0.31 (0.16–0.59) NA
Ondansetron vs placebo NA 169.61 (9.48–3035.34) NA
Granisetron vs palonosetron + steroid NA 0.37 (0.29–0.49) NA
Granisetron vs ramosetron + steroid NA 0.31 (0.16–0.60) NA
Granisetron vs placebo 1 168.85 (9.51–2996.64) 169.00
(9.52–2999.80)
Palonosetron vs placebo NA 165.47 (6.55–4182.08) NA
Palonosetron + steroid vs tropisetron NA 5.16 (2.43–10.97) NA
Palonosetron + steroid vs placebo NA 452.19 (25.18–8121.41) NA
Tropisetron vs ramosetron NA 0.35 (0.14–0.83) NA
Tropisetron vs ramosetron + steroid NA 0.16 (0.06–0.42) NA
Tropisetron vs placebo NA 87.64 (4.53–1696.76) NA
Ramosetron vs ramosetron + steroid 1 0.46 (0.29–0.73) 0.55 (0.34–0.89)
Ramosetron vs placebo NA 253.30 (13.55–4734.53) NA
Ramosetron + steroid vs placebo NA 546.71 (28.58–10,456.90) NA
Evaluation of inconsistency using the design-by-treatment
interaction model
Chi-squared test: 11.95 P-value: 0.0631
Degrees of freedom: 6 Heterogeneity: 0.00
Number of patients experiencing severe vomiting – 10 RCTs, 5 treatments, 917 adults
Ondansetron vs granisetron 4 0.65 (0.45–0.94) 0.63 (0.43–0.93)
Ondansetron vs placebo 3 0.16 (0.04–0.70) 0.16 (0.04–0.70)
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standard scales for collection of harms data, reporting
of whether harms encompassed all patients or a sam-
ple of patients, and number of harmful events re-
ported for each group, which were commonly scored
unclear overall.
Number of patients without nausea
NMA for the secondary outcome of the number of pa-
tients without nausea within 24 h was attempted with 47
RCTs and 11,778 patients, as well as a NMA including
51 studies with 12,188 patients (including randomized
and non-randomized studies), yet statistically significant
inconsistency was observed for both NMAs.
NMA for the 44 RCTs (n = 11,664 adults) investigating
12 treatments plus placebo (Fig. 2, Additional file 4:
Appendix A) showed that all of the treatments were sig-
nificantly superior to placebo in increasing the proportion
of patients without nausea (Table 3, Additional file 3:
Appendices K, L). In this analysis, dolasetron + steroid
had the highest SUCRA (Fig. 3, Additional file 3: Appen-
dix M), with a 95% probability of being the most effective
agent, followed closely by tropisetron + steroid (89%
Table 3 Statistically significant results of network meta-analysis in randomized controlled trials (Continued)
Ramosetron vs placebo NA 0.18 (0.03–0.95) NA
Evaluation of inconsistency using the design-by-treatment
interaction model
Chi-squared test: 0.33 P-value: 0.5628
Degrees of freedom: 1 Heterogeneity: 0.00
CI confidence interval, CINV chemotherapy-induced nausea and vomiting, MA meta-analysis, NA not applicable, NMA network meta-analysis, OR odds ratio,
RCT randomized controlled trial
a Meta-analysis was not conducted for treatment comparisons where only one trial was included; in that situation, the direct estimate was obtained from the
single trial
b Number of interventions included in NMA is greater than number of RCTs
Fig. 3 Rank-heat plot including adults in randomized controlled trials. Abbreviations: DOLA dolasetron, STER steroid, GRAN granisetron, DEX
dexamethasone, METO metoclopramide, ONDA ondansetron, PALO palonosetron, PLAC placebo, RAMO ramosetron, TROP tropisetron, No Vx
number of patients without vomiting, No Nx number of patients without nausea, No Vx&Nx number of patients without chemotherapy-induced
nausea and vomiting, Severe Vx number of patients experiencing severe vomiting
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probability). The same results were observed in another
subgroup analysis for patients who received cisplatin
chemotherapy (23 RCTs and 6259 patients) (Additional file
3: Appendix N). In an analysis of three pediatric RCTs of
four treatments (granisetron, ondansetron, palonosetron,
tropisetron; n = 293 children), palonosetron was statistically
significantly superior to ondansetron, and granisetron was
statistically significantly superior to tropisetron. Palonose-
tron had the highest SUCRA (88% probability).
A sensitivity analysis was conducted with 14 RCTs
assessed as having a low risk of randomization bias
(n = 4970 patients, 10 treatments). Ondansetron was
superior to dolasetron and granisetron, while all other
comparisons were superior to ondansetron. However, only
palonosetron + steroid, granisetron + steroid, ondansetron
+ steroid, and ramosetron + steroid were statistically sig-
nificantly superior to ondansetron (Additional file 3: Ap-
pendix N). Ramosetron + steroid had the highest SUCRA
(94% probability). Another sensitivity analysis was con-
ducted that included 14 RCTs with a low risk of allocation
concealment bias (n = 4199 patients, nine treatments). All
treatments except dolasetron increased the proportion of
patients without nausea versus ondansetron. However,
only palonosetron + steroid, granisetron + steroid, ondan-
setron + steroid, and dolasetron + steroid were statistically
significant. Dolasetron + steroid had the highest SUCRA
(95% probability). A third sensitivity analysis was
conducted including 11 RCTs with a low risk of blinding
bias (n = 3858 patients, seven treatments). Compared to
ondansetron, all treatments except dolasetron and grani-
setron increased the proportion of patients without nau-
sea. However, only granisetron + steroid, ondansetron +
steroid, and palonosetron were statistically significant.
Palonosetron had the highest SUCRA (99% probability).
NMA was conducted with 31 RCTs (n = 8108 patients,
30 treatments plus placebo) for the number of patients
without nausea more than 24 h after chemotherapy. All of
the dosing schedules and medications were superior to
placebo, but only the following schedules were statistically
significant: ondansetron + steroid on day 1 of chemother-
apy and at least one subsequent day, palonosetron on day
1 of chemotherapy, ondansetron + steroid on day 1 of
chemotherapy and at least one subsequent day +metoclo-
pramide on days 2–5 of chemotherapy, and tropisetron +
steroid on day 1 of chemotherapy and at least one subse-
quent day. The last of these schedules had the highest
SUCRA (96% probability). Notably, dolasetron + steroid
was not included in this NMA because none of the studies
reported this intervention.
Number of patients without vomiting
NMA for the secondary outcome of number of patients
without vomiting within 24 h after chemotherapy was
conducted with 71 RCTs (n = 16,300 adults, 12 treatments
plus placebo; Additional file 4: Appendix B). All of the
treatments were statistically significantly superior to pla-
cebo for this outcome (Additional file 3: Appendix O).
Palonosetron + steroid had the highest SUCRA (90%
probability; Additional file 3: Appendix P), followed
closely by tropisetron + steroid (79% probability). The
same results were observed in another analysis that in-
cluded 75 randomized and non-randomized studies (n =
16,710 patients, 12 treatments plus placebo), as well as
subgroup analysis including 63 RCTs with 15,460 adults,
and 12 treatments plus placebo (Figs 2 and 3, Table 3,
Additional file 3: Appendix Q). Similar results were ob-
served in another subgroup analysis including 69 RCTs
and 15,742 patients who received cisplatin chemotherapy
(12 treatments plus placebo); however, in this subgroup
analysis, dolasetron + steroid and tropisetron + steroid
both had a higher SUCRA (89% probability) than palono-
setron + steroid (78% probability). In an analysis of five
pediatric RCTs including a total of 411 children and test-
ing six treatments plus placebo (granisetron, ondansetron,
ondansetron + steroid, palonosetron, tropisetron, placebo),
granisetron and tropisetron were statistically significantly
superior to placebo, and granisetron had the highest
SUCRA (84% probability).
A sensitivity analysis was conducted including 21 RCTs
assessed as having a low risk of randomization bias (n =
6549 patients, 10 treatments plus placebo). Relative to pla-
cebo, all treatments increased the proportion of patients
without vomiting, although none of the results were statisti-
cally significant (Additional file 3: Appendix Q). The highest
SUCRA values were found in palonosetron + steroid (84%
probability) and ramosetron + steroid (81% probability). An-
other sensitivity analysis was conducted including 21 RCTs
with a low risk of allocation concealment bias (n = 6315 pa-
tients, 11 treatments). Relative to ondansetron, all treat-
ments except dolasetron increased the proportion of
patients without vomiting. The proportion of patients with-
out vomiting was statistically significantly higher with palo-
nosetron, palonosetron + steroid, and ondansetron + steroid
versus ondansetron. Palonosetron + steroid had the highest
SUCRA (73% probability). A third sensitivity analysis was
conducted including 20 RCTs with a low risk of blinding
bias (n = 6232 patients, nine treatments plus placebo). Com-
pared with placebo, all treatments statistically significantly
increased the proportion of patients without vomiting. The
highest SUCRA values were found for palonosetron (81%
probability), palonosetron + steroid (81% probability), and
ondansetron + steroid (79% probability).
NMA was attempted with 48 RCTs (n = 9425 patients)
that reported the number of patients without vomiting
more than 24 h after chemotherapy. However, there was
inconsistency between direct and indirect evidence.
Therefore, a subgroup analysis was conducted with 45
RCTs involving only adults (n = 8845 patients, 26
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treatments plus placebo). All of the dosing schedules and
medications were numerically superior to placebo and
there were 21 treatments that were also statistically super-
ior to placebo. However, the following schedules were not
statistically significant: ramosetron only on day 1 of
chemotherapy, dolasetron only on day 1 and at least one
subsequent day, ramosetron + steroid on day 1 and at least
one subsequent day, and granisetron + steroid on day 1
and at least one subsequent day. Dolasetron + steroid on
day 1 had the highest SUCRA (94% probability) along with
palonosetron + steroid on day 1 (94% probability).
Number of patients without CINV
NMA was attempted for the secondary outcome of
number of patients without CINV within 24 h of chemo-
therapy including 28 RCTs with 11,252 patients, as well
as a second NMA including 26 studies with 10,014
patients (including randomized and non-randomized
studies), yet statistically significant inconsistency was
observed in both NMAs.
NMA for 27 RCTs involving 10,924 adults (nine treat-
ments plus placebo) was conducted (Fig. 2, Additional
file 4: Appendix C). All of the treatments were statisti-
cally significantly superior to placebo for this outcome
(Table 3, Additional file 3: Appendices K, R). Ramose-
tron + steroid had the highest SUCRA (93% probability),
followed by palonosetron + steroid (91% probability;
Fig. 3, Additional file 3: Appendix S). Similar results
were observed in another subgroup analysis including 15
RCTs and 5250 patients receiving cisplatin chemother-
apy (nine treatments plus placebo; Additional file 3: Ap-
pendix T). In another subgroup analysis including eight
RCTs for 3066 patients who did not receive cisplatin
chemotherapy and seven treatments, palonosetron + ster-
oid, ondansetron + steroid, and granisetron + steroid were
statistically significantly superior to ondansetron and had
the highest SUCRAs (Additional file 3: Appendix T).
A sensitivity analysis was conducted including eight RCTs
assessed as having a low risk of randomization bias (n =
3677 patients, five treatments). Compared to ondansetron,
all treatments except granisetron significantly increased the
proportion of patients without CINV (Additional file 3: Ap-
pendix T). Palonosetron + steroid had the highest SUCRA
(85% probability). A second sensitivity analysis was con-
ducted including five RCTs with a low risk of allocation
concealment bias (n = 2771 patients, four treatments).
Granisetron + steroid, palonosetron + steroid, and ondan-
setron + steroid increased the proportion of patients with-
out CINV versus ondansetron, yet granisetron + steroid
was not statistically significant. Ondansetron + steroid had
the highest SUCRA (89% probability).
NMA was conducted with 26 RCTs (n = 8851 patients,
22 treatments plus placebo) that reported the number of
patients without CINV at more than 24 h after
chemotherapy. All treatments reduced the risk of CINV
relative to placebo, and the reduction was statistically
significant for the following regimens: ondansetron on
day 1 of chemotherapy only + steroid on day 1 and at
least one subsequent day, granisetron on day 1 only,
ondansetron + steroid on day 1 and at least one subse-
quent day, granisetron on day 1 only + steroid on day 1
and at least one subsequent day, palonosetron on day 1
only, dolasetron on day 1 and at least one subsequent
day + steroid on day 1 only, ondansetron + steroid on
day 1 and at least one subsequent day with metoclopra-
mide on days 2–5, palonosetron on day 1 only + steroid
on day 1 and at least one subsequent day, tropisetron +
steroid on day 1 and at least one subsequent day, and
ramosetron on day 1 and at least one subsequent day.
Ramosetron on day 1 and at least one subsequent day
had the highest SUCRA (90% probability), followed by
tropisetron + steroid on day 1 and at least one subse-
quent day (88% probability).
Number of patients experiencing severe vomiting
NMA was conducted for the secondary outcome of
number of patients experiencing severe vomiting (de-
fined as vomiting five times or more) within 24 h after
chemotherapy. In this analysis, 11 RCTs, 1364 adults,
and six treatments plus placebo were included (Fig. 2,
Additional file 4: Appendix D). All treatments were su-
perior to placebo in reducing the risk of severe vomiting,
but only ondansetron and ramosetron were statistically
significantly superior (Table 3, Additional file 3: Appen-
dices K, U). Ondansetron + steroid had the highest
SUCRA (80% probability), followed closely by ondanse-
tron (73% probability; Additional file 3: Appendix V).
Similar results were observed in a secondary analysis in-
cluding 13 randomized and non-randomized study de-
signs (n = 1600 patients, eight treatments plus placebo),
except that tropisetron + steroid had the highest SUCRA
(83% probability). The same results as the primary ana-
lysis were observed in a subgroup analysis including seven
RCTs and 677 adults receiving cisplatin chemotherapy
(six treatments plus placebo) (Additional file 3: Appendix
W).
Discussion
We conducted a systematic review and NMA on 5-HT3
receptor antagonists for patients undergoing chemother-
apy. Our results suggest that all treatments are relatively
safe, but we were unable to conduct an NMA on sudden
cardiac death, prolonged QRS interval, or delirium be-
cause of a dearth of data. Future RCTs to examine the
safety of these treatments should include these import-
ant outcomes. As well, the studies included in our
NMAs of arrhythmia, QTc prolongation, and mortality
did not have a placebo comparator, and we are therefore
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unable to comment on the safety of these treatments
relative to placebo.
Overall, our results suggest that all of these treatments
are effective for reducing nausea and vomiting experi-
enced by patients undergoing chemotherapy. According
to the rank-heat plot, the treatment that is most likely
the safest and most effective is palonosetron + steroid.
Our findings can be used by patients and their clinicians
to tailor their choice of treatments. For example, if a pa-
tient is most concerned about CINV during the first
24 h after chemotherapy, then ramosetron + steroid may
be the best choice. Across the effectiveness outcomes,
the following treatments ranked as most superior on
three effectiveness outcomes during the first 24 h after
chemotherapy for adults: ondansetron + steroid, palono-
setron + steroid, granisetron + steroid, and ramosetron +
steroid. If a patient is most concerned about CINV
occurring more than 24 h after chemotherapy, then
ramosetron given on day 1 and at least one subsequent
day, tropisetron + steroid given on day 1 and at least one
subsequent day, or palonosetron given on day 1 + steroid
given on day 1 and at least one subsequent day are po-
tentially effective options.
For the outcome of the number of patients without
vomiting, some nuances in the results are worth men-
tioning. In the NMA for the proportion of patients with-
out vomiting more than 24 h after chemotherapy,
dolasetron + steroid administered on day 1 of chemo-
therapy ranked high in the SUCRA analysis. However,
dolasetron + steroid did not rank highest in the SUCRA
analysis for the proportion of patients without vomiting
within 24 h after chemotherapy. This apparent discrep-
ancy might be due to the structure of the different
networks. For example, different interventions were in-
cluded between the studies assessing treatment within
24 h of chemotherapy versus those targeting vomiting
more than 24 h after chemotherapy, which might have
affected the results. The differing results might also be
attributable to heterogeneity, given that some treatment
comparisons will have different magnitudes than others
included in each NMA.
For the NMA on severe vomiting, the combination of
ondansetron + steroid was numerically superior to all of
the other treatments, but the results were not statisti-
cally significant. This might be due to a lack of power
because only one small RCT (n = 20 patients) examined
ondansetron + steroid versus ondansetron. However, be-
cause of the large effect sizes, this treatment ranked high
on the SUCRA analysis. Therefore, the SUCRA results
for the outcome of severe vomiting should be inter-
preted with caution.
We are aware of four previous systematic reviews that
examined 5-HT3 receptor antagonists for nausea and
vomiting [24–27]. Only two of these reviews examined
harms, such as dizziness, fever, headaches, and constipa-
tion [26, 27]. We included more studies (n = 200) and
more patients (n = 30,864) than any of these reviews
(Additional file 3: Appendix X), but we also excluded
some of the studies that were included in those earlier
reviews; reasons for those exclusions are presented in
Additional file 3: Appendix Y.
The studies included in our NMAs had some limita-
tions. Most of the studies were small, with an average
sample size of 197 patients. This limitation is particularly
problematic for assessing harms, because larger sample
sizes are required to draw definitive conclusions. Ap-
proximately 40% of the included studies were funded by
pharmaceutical companies, which may have resulted in
funding bias. In addition, random sequence generation,
allocation concealment, and blinding were unclear for
more than half of the RCTs. All of the studies failed to
ensure that the outcome of interest (e.g., no nausea) was
present at the start of the study. In addition, few of the
included studies reported on the emetogenicity setting
(e.g., highly emetogenic chemotherapy). Despite these
methodological shortcomings, we did not observe
reporting bias or small-study effects in our comparison-
adjusted funnel plot analysis for all outcomes.
Our systematic review process also had some limita-
tions. Because of the large number of included studies,
revisions to our original protocol [21] were necessary.
For example, we were unable to include all conference
abstracts and reports written in languages other than
English. Moreover, we did not conduct a sensitivity ana-
lysis around the node selection for the NMA, as we as-
sumed that the effects of different doses and durations
were identical across treatments. We are now exploring
these assumptions in another study [47]. In addition,
clinical practice guidelines recommend prophylaxis with
a 5-HT3 receptor antagonist, steroid, and a NK1 recep-
tor antagonist, yet none of the included studies exam-
ined this combination of treatments. As such, our
effectiveness results should be interpreted with caution.
As well, NMA should only be attempted when the stud-
ies are sufficiently homogenous. As such, we explored
whether the transitivity assumption was upheld and
found that confounding variables were generally well
balanced across the treatment comparisons in our
NMA. However, some of the studies may not have re-
ported all important confounding variables so this is
a limitation of our study. Although we planned to in-
clude non-randomized studies in our analyses of
harms, we found only RCTs reporting the outcomes
of interest. Finally, we were unable to conduct an
analysis stratified by emetogenicity, because of varied
reporting of chemotherapy regimens and classification
of chemotherapy regimens by type of emetogenic
agent over time [9].
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Conclusions
From this study, we conclude that most 5-HT3 receptor
antagonists alone or combined with steroids decrease
the occurrence of nausea and/or vomiting. Most 5-HT3
receptor antagonists were relatively safe when compared
with each other, yet none of the studies compared active
treatment with placebo for harms. Dolasetron + dexa-
methasone may prolong the QTc compared to ondanse-
tron + dexamethasone. Additional studies are needed to
characterize the cardiac and cognitive safety of these
treatments. Until then, it would be prudent for clinicians
to obtain baseline electrocardiographic tracings before
prescribing these common, effective antiemetics to any
patients who are undergoing chemotherapy.
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